Where does Amir Nashat work?

Amir Nashat is Entrepreneur Partner at Polaris Partners and Board director at Dewpoint Therapeutics and Board director at Scholar Rock Holding Corp, Inc. and Board director at Camp4 Therapeutics Corp.

What does Amir Nashat invest in?

Amir Nashat invests in Biotech, Healthtech.

What check size does Amir Nashat write?

Amir Nashat typically writes checks of $300K – $2M.

What boards does Amir Nashat sit on?

Amir Nashat holds tracked board seats at 1366 Technologies, Adnexus Therapeutics, Agbiome, Athenix Corporation, aTYR PHARMA, Avila Therapeutics, CAMP4 Therapeutics, Camp4 Therapeutics Corp, Cartesian Therapeutics (NASDAQ: RNAC), Dewpoint Therapeutics.

What companies has Amir Nashat invested in?

Investments tracked here include Souffle Therapeutics.

Where did Amir Nashat go to school?

Amir Nashat studied at Massachusetts Institute of Technology (PhD, Chemical Engineering); University of California, Berkeley (MSc, Materials Science Engineering); University of California, Berkeley (BSc, Mechanical Engineering).

What awards has Amir Nashat received?

Completed his MIT doctorate as a Hertz Fellow. Named to the Forbes Midas List of Top 100 Venture Capitalists in 2016.

Amir Nashat

Investor

Entrepreneur Partner at Polaris Partners · Board director at Dewpoint Therapeutics · Board director at Scholar Rock Holding Corp, Inc. · Board director at Camp4 Therapeutics Corp

Boston

Writes $300K – $2M checks · typically $500K

About

Amir Nashat is an entrepreneur partner at Polaris Partners in Boston, where he invests in healthcare companies and takes on executive roles inside portfolio companies. He joined the firm in 2002 and serves as a managing partner of Polaris Funds VI through IX. He has repeatedly stepped in as CEO of Polaris-backed startups, including Dewpoint Therapeutics, Jnana, Living Proof, Olivo Labs, Paratus Sciences, and Sun Catalytix, and is currently CEO of Souffle Therapeutics. He earned a doctorate in chemical engineering at MIT under Robert Langer and holds materials science and mechanical engineering degrees from UC Berkeley, and was named to the Forbes Midas List in 2016.

Contact· published on Amir's own website

a•••@polarispartners.comreveal

Likely email· guessed from name + firm domain, not firm-published

a•••@polarispartners.comreveal100% confident

Invests in

BiotechHealthtech

Beyond investing

Education: Completed his ScD in Chemical Engineering with a minor in Biology at MIT under Dr. Robert Langer. Earned both his MS and BS in Materials Science and Mechanical Engineering at UC Berkeley.
Boards: Serves on the Partners Innovation Fund and the Investment Advisory Committee for The Engine at MIT. Helped launch the MIT Sandbox Innovation Fund and served as its active president.
Awards: Completed his MIT doctorate as a Hertz Fellow. Named to the Forbes Midas List of Top 100 Venture Capitalists in 2016.

From Amir's own website — common ground for a warm intro.

Board director at Dewpoint Therapeutics

Intro paths

→

In turn, Amir can intro founders to Dewpoint Therapeutics's investors below.

Dewpoint Therapeutics's investors · 12

3E Bioventures CapitalPalo Alto 6 Dimensions CapitalGrand Cayman ARCH Venture PartnersChicago · $50K – $250M checks EcoR1 CapitalSan Francisco General CatalystSan Francisco · $30M checks Innovation EndeavorsPalo Alto · $1M – $15M checks Leaps by BayerLeverkusen Maverick VenturesSan Francisco · $3M – $10M checks Mubadala CapitalAbu Dhabi · $1M – $50M checks Polaris PartnersBoston · $500K – $5M checks · since 2022 Samsara BioCapitalPalo Alto SoftBank Vision FundLondon

Co-founders at Dewpoint Therapeutics

Richard Young, Ph.D.Director

Anthony Hyman, Ph.D.Director

Tony HymanScientific Co-founder

Rick YoungScientific Co-founder

Board director at Scholar Rock Holding Corp, Inc.

Intro paths

→

In turn, Amir can intro founders to Scholar Rock Holding Corp, Inc.'s investors below.

Scholar Rock Holding Corp, Inc.'s investors · 3

ARCH Venture PartnersChicago · $50K – $250M checks · since 2017 Polaris PartnersBoston · $500K – $5M checks · since 2017 Samsara BioCapitalPalo Alto · since 2017

Co-founders at Scholar Rock Holding Corp, Inc.

Nagesh MahanthappaExecutive Officer, Director

Timothy SpringerDirector

Board director at Camp4 Therapeutics Corp

Intro paths

→

In turn, Amir can intro founders to Camp4 Therapeutics Corp's investors below.

Camp4 Therapeutics Corp's investors · 4

5AM VenturesBoston · $100K – $4M checks · since 2021 Andreessen HorowitzMenlo Park · $500K – $50M checks · since 2018 Longwood FundBoston · since 2021 Polaris PartnersBoston · $500K – $5M checks · since 2022

Experience

Soufflé TherapeuticsChief Executive Officercurrent2021 — present
CAMP4 TherapeuticsBoard Membercurrent2016 — presentCambridge, Massachusetts, United States
Dewpoint TherapeuticsBoard Membercurrent2018 — presentBoston, Massachusetts, United States
Dewpoint TherapeuticsChief Executive Officer2018 — 2020
Institute for Protein InnovationBoard Membercurrent2017 — present
Polaris Venture PartnersEntrepreneur Partnercurrent2021 — present
Polaris Venture PartnersManaging General Partner2002 — 2021
Polaris Venture PartnersManaging Partner2002 — 2021Boston, Massachusetts, United States
AgBiomeBoard Member2012 — 2024
Morphic TherapeuticBoard Member2017 — 2024
Scholar RockBoard Member2012 — 2024Cambridge, Massachusetts
Metacrine, Inc.Board Member2014 — 2023La Jolla, California
Paratus SciencesChief Executive Officer2020 — 2022New York City Metropolitan Area
Syros PharmaceuticalsBoard Member2014 — 2022Cambridge, Massachusetts
FreenomeBoard Member2019 — 2021
Fate Therapeutics IncBoard Member2008 — 2020
Jnana TherapeuticsCEO2017 — 2018
Promedior, Inc.Board Member2008 — 2018Greater Boston Area
Receptos, Inc.Board Member2012 — 2014
AVILA THERAPEUTICS, INC.Board Member2007 — 2012
Living Proof, Inc.Board Member2005 — 2011
Living Proof, Inc.CEO2005 — 2006

Deals · 15

Morphic Holding, Inc.Board seat

via Polaris Partners · filed Mar 2023 · $100M raise

Camp4 Therapeutics CorpBoard seat

via Polaris Partners · filed Jun 2022

AgbiomeBoard seat

via Polaris Partners · filed Feb 2022 · $117.2M raise

Dewpoint TherapeuticsBoard seat

via Polaris Partners · filed Feb 2022 · $150M raise

Syros Pharmaceuticals, Inc.Board seat

via Polaris Partners · filed Dec 2020 · $121.6M raise

Primmune TherapeuticsBoard seat

via Polaris Partners · filed Nov 2020 · $24M raise

Freenome HoldingsBoard seat

via Polaris Partners · filed Aug 2020 · $270M raise

Cartesian Therapeutics (NASDAQ: RNAC)Board seat

via Polaris Partners · filed Jan 2020 · $70M raise

Scholar Rock Holding Corp, Inc.Board seat

via Polaris Partners · filed Jan 2018 · $47M raise

SofregenBoard seat

via Polaris Partners · filed Sep 2017 · $9.7M raise

MetacrineBoard seat

via Polaris Partners · filed Nov 2016 · $37.8M raise

Fate TherapeuticsBoard seat

via Polaris Partners · filed Aug 2016 · $10.3M raise

1366 TechnologiesBoard seat

via Polaris Partners · filed May 2016 · $30M raise

Scholar RockBoard seat

via Polaris Partners · filed Jan 2016 · $40M raise

aTYR PHARMABoard seat

via Polaris Partners · filed Apr 2015 · $76.3M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

Adnexus TherapeuticsAthenix CorporationAvila TherapeuticsCAMP4 TherapeuticsFreenomeLiving ProofMetacrine TherapeuticsMorphic TherapeuticParatus SciencesPromedior PharmaceuticalsReceptosSelecta BiosciencesSun CatalytixSyros PharmaceuticalsTARIS Biomedical

Investor

Souffle Therapeutics

Sources: SEC Form D filings · the firm's website.

Colleagues at Polaris Partners

Alan Crane

Entrepreneur Partner at Polaris Partners

Alexandra Cantley

Managing Partner at Polaris Partners

Alicia Taylor

Investment Director at Pembroke VCT

Amy Schulman

Managing Partner at Polaris Partners

Annie Wihongi

Executive Assistant and Office Manager at Polaris Partners

Brian Chee

Managing Partner at Polaris Partners

Brian Lewis

Director, Legal & Investment Analytics at Polaris Partners

Chen-Ee Lee

Partner at Polaris Partners

Network5

Aymeric Sallin

Founder and CEO at +ND Capital

Carlo Rizzuto

Managing Director at Versant Ventures

Paul Berns

Managing Director at ARCH Venture Partners

Peter Kolchinsky

Managing Partner at RA Capital

Vasudev Bailey

General Partner at Artis Ventures

Investors connected to Amir in public investor directories — a warm-intro map.

Frequently asked questions

Who is Amir Nashat?: Amir Nashat is an entrepreneur partner at Polaris Partners in Boston, where he invests in healthcare companies and takes on executive roles inside portfolio companies. He joined the firm in 2002 and serves as a managing partner of Polaris Funds VI through IX. He has repeatedly stepped in as CEO of Polaris-backed startups, including Dewpoint Therapeutics, Jnana, Living Proof, Olivo Labs, Paratus Sciences, and Sun Catalytix, and is currently CEO of Souffle Therapeutics. He earned a doctorate in chemical engineering at MIT under Robert Langer and holds materials science and mechanical engineering degrees from UC Berkeley, and was named to the Forbes Midas List in 2016.
Where does Amir Nashat work?: Amir Nashat is Entrepreneur Partner at Polaris Partners and Board director at Dewpoint Therapeutics and Board director at Scholar Rock Holding Corp, Inc. and Board director at Camp4 Therapeutics Corp.
What does Amir Nashat invest in?: Amir Nashat invests in Biotech, Healthtech.
What check size does Amir Nashat write?: Amir Nashat typically writes checks of $300K – $2M.
What boards does Amir Nashat sit on?: Amir Nashat holds tracked board seats at 1366 Technologies, Adnexus Therapeutics, Agbiome, Athenix Corporation, aTYR PHARMA, Avila Therapeutics, CAMP4 Therapeutics, Camp4 Therapeutics Corp, Cartesian Therapeutics (NASDAQ: RNAC), Dewpoint Therapeutics.
What companies has Amir Nashat invested in?: Investments tracked here include Souffle Therapeutics.
Where did Amir Nashat go to school?: Amir Nashat studied at Massachusetts Institute of Technology (PhD, Chemical Engineering); University of California, Berkeley (MSc, Materials Science Engineering); University of California, Berkeley (BSc, Mechanical Engineering).
What awards has Amir Nashat received?: Completed his MIT doctorate as a Hertz Fellow. Named to the Forbes Midas List of Top 100 Venture Capitalists in 2016.